[Chemotherapy of disseminated forms of breast cancer using platinum derivatives]. / Khimioterapiia rasprostranennykh form raka molochnoi zhelezy s ispol'zovaniem proizvodnykh platiny.

Platinum-based combination chemotherapy regimens (CAP or CMF + cisplatin) were used for the treatment of disseminated breast cancer. Response rate for the CAP regimen was 47.5%. The most frequent side-effects were nausea, vomiting, nephrotoxicity and myelosuppression. Relationship between survival and response was identified.

[Tactics in treating patients with small cell cancer of the lung with superior vena cava obstruction syndrome]. / Taktika lecheniia bolnykh melkokletochnym rakom legkogo s sindromom sdavleniia verkhnei poloi veny.

A non-randomized study was carried out to evaluate the immediate and end results of chemo-radiation therapy of 44 cases of small-cell lung cancer aggravated with superior vena cava obstruction syndrome. Both radiation and chemotherapy proved effective in urgent combatting said syndrome. The best results were reliably secured when chemotherapy was supported with radiotherapy at an earlier possible stage. Due to gravity of their condition such case require the therapy as an urgent measure. The treatment proved effective as 40% of patients with localized small-cell lung tumors and the syndrome survived 12 months.

[Chemoradiation treatment of the superior vena cava compression syndrome in small-cell lung cancer]. / Khimioluchevoe lechenie sindroma sdavleniia verkhnei poloi veny pri melkokletochnom rake legkogo.

The superior vena cava compression syndrome (SVCCS) was detected in 340 patients with small cell lung carcinoma (SCLC): in 44--during establishing primary diagnosis (the primary syndrome), in 10--after courses of chemo- or radiotherapy (the secondary syndrome). In 32 patients with the primary SVCCS therapy was started with chemotherapy courses, a complete clinical effect was noted in 20 (62.5%) of them, on an average, in 11.7 days. Radiotherapy or chemo- and radiotherapy were given to 32 patients: to 12 patients as kind of primary therapy, to 12 patients after a partial effect of chemotherapy, and to 8 patients with the secondary SVCCS. A complete clinical effect was noted in 28 (87.5%) patients, on an average, in 23 days. Complete and partial tumor regressions (an objective effect) were noted in 30% of the patients after chemotherapy and in 75%--after radiotherapy or chemo- and radiotherapy. Marked responses to therapy were noted in single administration of chemotherapeutic drugs at large doses (leukopenia below 2000 cells/microliter, vomiting) or in irradiation of the thoracic cavity at single doses of 3-6 Gy (esophagitis). The authors recommended to plan chemo- and radiotherapy at mean doses in patients with the primary SVCCS, in a localized process or distant metastases, not threatening the patient's life. In the secondary SVCCS developing after chemotherapy, a method of choice is radiotherapy using single doses of 4-6 Gy, 5-8 fractions.

[Scalp hypothermia as a preventive of alopecia in patients receiving combined chemotherapy including anthracyclines]. / Gipotermiia volosistoi chasti golovy kak profilaktika alopetsii u bol'nykh, poluchaiushchikh kombinirovannuiu khimioterapiiu s ispol'zovaniem antratsiklinov.

Scalp cooling to prevent alopecia was used in 47 patients treated with anthracyclines for various tumors. Good results were obtained though the course included cyclophosphamide which also causes alopecia. Total beneficial (good + satisfactory) effect was recorded in 36 patients (74.4%) who did not need a wig.

[Efficacy of doxorubicin (adriamycin) in disseminated forms of breast cancer]. / Effektivnost' doksirubitsina (adriamitsina) pri disseminirovannykh formakh raka molochnoi zhelezy.

The efficacy of doxorubicin used alone or in combination with other drugs in chemotherapy of 53 patients with disseminated breast cancer was studied. Doxorubicin combinations with vincristine, cyclophosphamide, 5-fluorouracil and cyclophosphamide, 5-fluorouracil, cyclophosphamide and methotrexate were used. The efficacy of the treatment amounted to 35--50 per cent. Alopecia and hemopoiesis inhibition were the main adverse reactions. Over the past years a new combination of cyclophosphamide, doxorubicin (adriamycin) and cis-platinum was used in the treatment of 45 patients with disseminated breast cancer. The objective effect was observed in 14 patients (38.9 per cent). In 4 of them complete tumor regression was recorded. The administration regimens and side effects of the drugs are described.

[Experience in using a combination of olivomycin with cyclophosphane in treating malignant testicular tumors of heterogeneous structure]. / Opyt primeneniia kombinatsii olivomitsina s tsiklofosfanom pri lechenii zlokachestvennykh opukholei iaichka neodnorodnogo stroeniia.

Clinical trials of the combination of olivomycin with cyclophosphamide were performed on 41 patients with testicle tumours of heterogenous structure. Objective effects were observed in 70.7 per cent of the cases, an effect higher than 50 per cent was recorded in 46.3 per cent of the patients and complete regression of the tumours was achieved in 17.1 per cent of the cases. The combination of olivomycin with cyclophosphamide was well tolerated by the patients. The most frequent side effects of the combination were leucopenia, thrombocytopenia, nausea and vomiting.

[Trial of the clinical use of mithramycin in treating testicular cancer]. / Opyt klinicheskogo primeneniia mitramitsina pri lechenii raka iaichka.

The data on efficacy of mitramycin, an antitumor antibiotic in treatment of 32 patients with cancer of the testicle are presented. The objectively pronounced effect was observed in 37.5 per cent of the cases, mitramycin being effective in patients with tumors resistant to bleomycin, vinblastin and cis-dichlordiaminoplatinum. Nausea and vomiting were the most frequent side effects of mitramycin use. The hemorrhagic syndrome was recorded in 2 patients. The regimen of the mitramycin intravenous administration in a dose of 25--30 microgram/kg once in 2 days was well tolerated by the patients and may be recommended for the treatment of testicle cancer.